RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-11-05
DOI
10.1038/s41467-021-26018-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial
- (2020) Denise M. Wolf et al. npj Breast Cancer
- Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
- (2019) Filippo Montemurro et al. EUROPEAN JOURNAL OF CANCER
- Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
- (2019) Edith A. Perez et al. CANCER
- Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients
- (2019) Max Hardy-Werbin et al. Scientific Reports
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study
- (2017) Alessandra Fabi et al. Oncotarget
- Current and emerging therapies of HER2-positive metastatic breast cancer
- (2016) Abraham Hernández-Blanquisett et al. BREAST
- Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
- (2016) J. Baselga et al. CLINICAL CANCER RESEARCH
- Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature
- (2016) María Teresa Martínez et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1)vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer
- (2016) Sung-Bae Kim et al. INTERNATIONAL JOURNAL OF CANCER
- Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance
- (2016) Rachelle L. Dillon et al. JOURNAL OF IMMUNOTHERAPY
- Targeting HER2 for the Treatment of Breast Cancer
- (2015) Mothaffar F. Rimawi et al. Annual Review of Medicine
- A RAB5/RAB4 recycling circuitry induces a proteolytic invasive program and promotes tumor dissemination
- (2014) Emanuela Frittoli et al. JOURNAL OF CELL BIOLOGY
- Pragmatic issues in biomarker evaluation for targeted therapies in cancer
- (2014) Armand de Gramont et al. Nature Reviews Clinical Oncology
- Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer
- (2014) Jessica M Baron et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
- (2013) Nadia Harbeck et al. Breast Care
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
- (2013) Michael Ritchie et al. mAbs
- The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments
- (2012) Katia Cortese et al. MOLECULAR BIOLOGY OF THE CELL
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Rab GTPases as coordinators of vesicle traffic
- (2009) Harald Stenmark NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Pathways and mechanisms of endocytic recycling
- (2009) Barth D. Grant et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search